Interferon decreases VEGF levels in patients with chronic myeloidleukemia treated with imatinib

被引：15
作者：
Legros, L. [1 ,2 ]
Guilhot, J. [2 ,3 ]
Huault, S.
Mahon, F. X. [4 ]
Preudhomme, C. [5 ,6 ]
Guilhot, F. [3 ]
Hueber, A. O. [2 ]
机构：
[1] Hop Archet 1, Serv Hematol Clin, F-06202 Nice 2, France
[2] CNRS, Inst Biol Valrose iBV, UMR 7277, UMR INSERM 1091, Nice, France
[3] CHU Poitiers, Inserm CIC 0802, Poitiers, France
[4] Univ Bordeaux Segalen, Ctr Hosp Univ Bordeaux, INSERM 1035, Lab Hematol & Serv Malad Sang,Inst Bergonie, Bordeaux, France
[5] CHU Lille, Hematol Lab, F-59037 Lille, France
[6] INSERM, U837, F-59045 Lille, France
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷 / 06期
关键词：
Vascular Endothelial Growth Factor (VEGF); Imatinib; Chronic myeloid leukemia (CML); Angiogenesis; Interferon-alpha; ENDOTHELIAL GROWTH-FACTOR; CHRONIC MYELOID-LEUKEMIA; CELL GROWTH; ANGIOGENESIS; ALPHA;
D O I：
10.1016/j.leukres.2014.01.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In chronic myeloid leukemia (CML), evidence is supporting the role of VEGF in growth, and survival of leukemia cells. The evaluation of plasma VEGF levels in 403 CML patients randomized within SPIRIT study to received imatinib-400 mg versus imatinib + cytarabine versus imatinib + interferon (IFN) versusimatinib-600 mg demonstrated that VEGF is an independent factor of BCR-ABL burden. VEGF low levels at diagnosis were associated with a progression-free survival of 100% at 48 months. Under treatment, significant lowest levels were observed in imatinib + IFN arm. These results support the use of VEGF as a parameter to predict CML evolution and let us to speculate about antiangiogenic properties of IFN. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：662 / 665
页数：4
相关论文
共 21 条
  • [1] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
    Aguayo, A
    Kantarjian, H
    Manshouri, T
    Gidel, C
    Estey, E
    Thomas, D
    Koller, C
    Estrov, Z
    O'Brien, S
    Keating, M
    Freireich, E
    Albitar, M
    [J]. BLOOD, 2000, 96 (06) : 2240 - 2245
  • [2] Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
    Baccarani, Michele
    Cortes, Jorge
    Pane, Fabrizio
    Niederwieser, Dietger
    Saglio, Giuseppe
    Apperley, Jane
    Cervantes, Francisco
    Deininger, Michael
    Gratwohl, Alois
    Guilhot, Francois
    Hochhaus, Andreas
    Horowitz, Mary
    Hughes, Timothy
    Kantarjian, Hagop
    Larson, Richard
    Radich, Jerald
    Simonsson, Bengt
    Silver, Richard T.
    Goldman, John
    Hehlmann, Rudiger
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) : 6041 - 6051
  • [3] Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
    Bellamy, WT
    Richter, L
    Sirjani, D
    Roxas, C
    Glinsmann-Gibson, B
    Frutiger, Y
    Grogan, TM
    List, AF
    [J]. BLOOD, 2001, 97 (05) : 1427 - 1434
  • [4] Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
    Dias, S
    Hattori, K
    Zhu, ZP
    Heissig, B
    Choy, M
    Lane, W
    Wu, Y
    Chadburn, A
    Hyjek, E
    Gill, M
    Hicklin, DJ
    Witte, L
    Moore, MAS
    Rafii, S
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (04) : 511 - 521
  • [5] Role of vascular endothelial growth factor in Physiologic and Pathologic angiogenesis: Therapeutic implications
    Ferrara, N
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (06) : 10 - 14
  • [6] Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
    Fiedler, W
    Graeven, U
    Ergun, S
    Verago, S
    Kilic, N
    Stockschlader, M
    Hossfeld, DK
    [J]. BLOOD, 1997, 89 (06) : 1870 - 1875
  • [7] Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts
    Hatfield, Kimberley
    Ryningen, Anita
    Corbascio, Matthias
    Bruserud, Oystein
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (10) : 2313 - 2321
  • [8] A family business: stem cell progeny join the niche to regulate homeostasis
    Hsu, Ya-Chieh
    Fuchs, Elaine
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2012, 13 (02) : 103 - 114
  • [9] Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches
    Konopleva, Marina
    Tabe, Yoko
    Zeng, Zhihong
    Andreeff, Michael
    [J]. DRUG RESISTANCE UPDATES, 2009, 12 (4-5) : 103 - 113
  • [10] Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study
    Korkolopoulou, P
    Viniou, N
    Kavantzas, N
    Patsouris, E
    Thymara, I
    Pavlopoulos, PM
    Terpos, E
    Stamatopoulos, K
    Plata, E
    Anargyrou, K
    Androulaki, A
    Davaris, P
    Yataganas, X
    [J]. LEUKEMIA, 2003, 17 (01) : 89 - 97
123